Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases
Abstract
Abstract Postbariatric hypoglycemia (PBH) represents a challenging complication of bariatric surgery. This case series describes 3 patients with PBH following Roux-en-Y gastric bypass who were treated with tirzepatide, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA). All patients presented with symptomatic hypoglycemia characterized by episodes of diaphoresis, visual disturbances, confusion, and documented low blood glucose levels occurring postprandially. Conventional management strategies, including dietary modifications, acarbose, and other pharmacotherapies, were either partially effective or limited by side effects. Initiation of tirzepatide led to increased time in range, reduced number and severity of hypoglycemic episodes, and decreased glucose variability. This report suggests that GLP-1 and GIP RA can be a promising adjunct in managing PBH; however, further studies to confirm their efficacy and establish optimal dosing strategies are needed.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.